ReviewFrontiers in immunology2020
The New Frontier of Host-Directed Therapies for
Review in Frontiers in immunology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it, 34 citations in OpenAlex.
- A systematic review of preclinical studies on therapeutic potential of mesenchymal stem/stromal cells and their secretome in bacterial infections.Stem cell research & therapy · 2025Pooled it
- Cutaneous MAC infection in an immunocompetent patient: a case report confirmed by mNGS.BMC infectious diseases · 2026Article
- Advancing Tuberculosis Chemotherapy: Targeted Nanomedicines for the Mycobacterium TB Granuloma.Small (Weinheim an der Bergstrasse, Germany) · 2025Review
- Review
- Article
- Autophagy in mycobacterial infections: molecular mechanisms, host-pathogen interactions, and therapeutic opportunities.Frontiers in cellular and infection microbiology · 2025Review
- Exploring the Chemical Space of Mycobacterial Oxidative Phosphorylation Inhibitors Using Molecular Modeling.ChemMedChem · 2024Review
- The Association between Dyslipidemia and Pulmonary Diseases.Journal of atherosclerosis and thrombosis · 2024Review
- Supporting Patients with Nontuberculous Mycobacterial Pulmonary Disease: Ensuring Best Practice in UK Healthcare Settings.Pharmacy (Basel, Switzerland) · 2024Review
- Preclinical murine models for the testing of antimicrobials against Mycobacterium abscessus pulmonary infections: Current practices and recommendations.Tuberculosis (Edinburgh, Scotland) · 2024Review
- Efficacy of SPR720 in murine models of non-tuberculous mycobacterial pulmonary infection.The Journal of antimicrobial chemotherapy · 2024Article
- Investigating cutaneous tuberculosis and nontuberculous mycobacterial infections a Department of Dermatology, Beijing, China: a comprehensive clinicopathological analysis.Frontiers in cellular and infection microbiology · 2024Article
- Article
- Metformin improvesFrontiers in immunology · 2024Article
- Treatment of non-tuberculosis mycobacteria skin infections.Frontiers in pharmacology · 2023Review
- Meeting the challenges of NTM-PD from the perspective of the organism and the disease process: innovations in drug development and delivery.Respiratory research · 2022Review
- Diagnosis and Management of Pulmonary NTM with a Focus onMicroorganisms · 2022Review
- Application of Precise Positioning for Sputum Expectoration in ICU Patients with Pulmonary Infection.Computational and mathematical methods in medicine · 2022Article
- Host-Pathogen Interactions Operative duringImmune network · 2021Review
- Personalised Medicine for Tuberculosis and Non-Tuberculous Mycobacterial Pulmonary Disease.Microorganisms · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.